Respiratory Syncytial Virus Vaccine Development

Clinics in Laboratory Medicine

Volumn 29, Issue 4, 2009, Pages 725-739

  Murata, Yoshihiko ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Cellular immunity; Humoral immunity; Respiratory syncytial virus; Respiratory tract infection; Vaccine

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SINGLE DRUG DOSE; VACCINATION; VACCINE PRODUCTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS PATHOGENESIS;

HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 70350515701     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.07.004     Document Type: Review

References (84)

1. Hall C.B., and McCarthy C.A. Respiratory syncytial virus. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practices of infectious disease vol. 6 (2004), Elsevier Churchill Livingstone, Philadelphia 2008-2026
2. Hall C.B., Walsh E.E., Long C.E., et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163 (1991) 693-698
3. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
4. Falsey A.R., Hennessey P.A., Formica M.A., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352 (2005) 1749-1759
5. Collins P.L., and Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82 (2008) 2040-2055
6. Taylor G., Stott E.J., Bew M., et al. Monoclonal antibodies protect against respiratory syncytial virus. Lancet 2 (1983) 976
7. Walsh E.E., Schlesinger J.J., and Brandriss M.W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 43 (1984) 756-758
8. Walsh E.E., Cote P.J., Fernie B.F., et al. Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol 67 (1986) 505-513
9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. IMpact-RSV Study Group. Pediatrics 102 (1998) 531-537
10. Zhang L., Peeples M.E., Boucher R.C., et al. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76 (2002) 5654-5666
11. Openshaw P.J., and Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18 (2005) 541-555
12. Braciale T.J. Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system. Proc Am Thorac Soc 2 (2005) 141-146
13. Graham B.S., Bunton L.A., Wright P.F., et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88 (1991) 1026-1033
14. Alwan W.H., Record F.M., and Openshaw P.J. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol 88 (1992) 527-536
15. Tang Y.W., and Graham B.S. T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest 99 (1997) 2183-2191
16. Peebles Jr. R.S., and Graham B.S. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2 (2005) 110-115
17. Murphy B.R., Sotnikov A.V., Lawrence L.A., et al. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8 (1990) 497-502
18. Openshaw P.J., Clarke S.L., and Record F.M. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4 (1992) 493-500
19. Collins P.L., and Murphy B.R. Vaccines against human respiratory syncytial virus. In: Cane P.A. (Ed). Respiratory syncytial virus (2007), Elsevier, Amsterdam 233-277
20. Fulginiti V.A., Eller J.J., Sieber O.F., et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89 (1969) 435-448
21. Kapikian A.Z., Mitchell R.H., Chanock R.M., et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 (1969) 405-421
22. Chin J., Magoffin R.L., Shearer L.A., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89 (1969) 449-463
23. Kim H.W., Canchola J.G., Brandt C.D., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 (1969) 422-434
24. Murphy B.R., and Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26 (1988) 1595-1597
25. Peebles Jr. R.S., Sheller J.R., Collins R.D., et al. Respiratory syncytial virus (RSV)-induced airway hyper-responsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis 182 (2000) 671-677
26. Prince G.A., Jenson A.B., Hemming V.G., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 57 (1986) 721-728
27. Belshe R.B., Van Voris L.P., and Mufson M.A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 145 (1982) 311-319
28. Collins P.L., and Murphy B.R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2 (2005) 166-173
29. Friedwald W., Forsyth B., Smith C., et al. Low-temperature grown RS virus in adult volunteers. JAMA 204 (1968) 142-146
30. Wright P.F., Karron R.A., Belshe R.B., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182 (2000) 1331-1342
31. Pringle C.R., Filipiuk A.H., Robinson B.S., et al. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11 (1993) 473-478
32. Whitehead S.S., Firestone C.Y., Karron R.A., et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 73 (1999) 871-877
33. Whitehead S.S., Firestone C.Y., Collins P.L., et al. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247 (1998) 232-239
34. Juhasz K., Whitehead S.S., Boulanger C.A., et al. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive, and attenuation mutations. Vaccine 17 (1999) 1416-1424
35. Whitehead S.S., Juhasz K., Firestone C.Y., et al. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72 (1998) 4467-4471
36. Teng M.N., Whitehead S.S., Bermingham A., et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74 (2000) 9317-9321
37. Karron R.A., Wright P.F., Belshe R.B., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 (2005) 1093-1104
38. Wright P.F., Karron R.A., Madhi S.A., et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 193 (2006) 573-581
39. Walsh E.E., Hall C.B., Briselli M., et al. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis 155 (1987) 1198-1204
40. Wathen M.W., Kakuk T.J., Brideau R.J., et al. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis 163 (1991) 477-482
41. Murphy B.R., Sotnikov A., Paradiso P.R., et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7 (1989) 533-540
42. Hancock G.E., Heers K.M., Pryharski K.S., et al. Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21 (2003) 4348-4358
43. Prince G.A., Denamur F., Deschamps M., et al. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19 (2001) 2048-2054
44. Delgado M.F., Coviello S., Monsalvo A.C., et al. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15 (2009) 34-41
45. Belshe R.B., Anderson E.L., and Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 168 (1993) 1024-1029
46. Tristram D.A., Welliver R.C., Mohar C.K., et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 167 (1993) 191-195
47. Paradiso P.R., Hildreth S.W., Hogerman D.A., et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 13 (1994) 792-798
48. Piedra P.A., Grace S., Jewell A., et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15 (1996) 23-31
49. Groothuis J.R., King S.J., Hogerman D.A., et al. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 177 (1998) 467-469
50. Piedra P.A., Cron S.G., Jewell A., et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multicenter trial in children with cystic fibrosis. Vaccine 21 (2003) 2448-2460
51. Falsey A.R., and Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14 (1996) 1214-1218
52. Munoz F.M., Piedra P.A., and Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 (2003) 3465-3467
53. Power U.F., Plotnicky-Gilquin H., Huss T., et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230 (1997) 155-166
54. de Waal L., Power U.F., Yuksel S., et al. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22 (2004) 915-922
55. Ison M.G., Mills J., Openshaw P., et al. Current research on respiratory viral infections: fourth international symposium. Antiviral Res 55 (2002) 227-278
56. Falsey A.R., Walsh E.E., Capellan J., et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 198 (2008) 1317-1326
57. Trudel M., Stott E.J., Taylor G., et al. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch Virol 117 (1991) 59-71
58. Singh S.R., Dennis V.A., Carter C.L., et al. Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice. Viral Immunol 20 (2007) 261-275
59. Singh S.R., Dennis V.A., Carter C.L., et al. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25 (2007) 6211-6223
60. Trudel M., Nadon F., Seguin C., et al. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G-glycoprotein. Virology 185 (1991) 749-757
61. Bastien N., Trudel M., and Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17 (1999) 832-836
62. Jennings G.T., and Bachmann M.F. The coming of age of virus-like particle vaccines. Biol Chem 389 (2008) 521-536
63. Siddiqui M.A., and Perry C.M. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66 (2006) 1263-1271 [discussion: 1272-3]
64. Woo W.P., Doan T., Herd K.A., et al. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol 80 (2006) 3975-3984
65. Roux X., Dubuquoy C., Durand G., et al. Subnucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One 3 (2008) e1766
66. Connors M., Collins P.L., Firestone C.Y., et al. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65 (1991) 1634-1637
67. Wyatt L.S., Whitehead S.S., Venanzi K.A., et al. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18 (1999) 392-397
68. Collins P.L., Purcell R.H., London W.T., et al. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8 (1990) 164-168
69. Crowe Jr. J.E., Collins P.L., London W.T., et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11 (1993) 1395-1404
70. de Waal L., Wyatt L.S., Yuksel S., et al. Vaccination of infant macaques with a recombinant modified vaccinia virus ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 22 (2004) 923-926
71. Takimoto T., Hurwitz J.L., Zhan X., et al. Recombinant sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol 18 (2005) 255-266
72. Tang R.S., Schickli J.H., MacPhail M., et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 77 (2003) 10819-10828
73. Schmidt A.C., McAuliffe J.M., Murphy B.R., et al. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75 (2001) 4594-4603
74. Schmidt A.C., Wenzke D.R., McAuliffe J.M., et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76 (2002) 1089-1099
75. Tang R.S., MacPhail M., Schickli J.H., et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78 (2004) 11198-11207
76. Cano F., Plotnicky-Gilquin H., Nguyen T.N., et al. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18 (2000) 2743-2752
77. Mok H., Lee S., Utley T.J., et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 81 (2007) 13710-13722
78. Elliott M.B., Chen T., Terio N.B., et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25 (2007) 7132-7144
79. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 80 (2006) 1130-1139
80. Dollenmaier G., Mosier S.M., Scholle F., et al. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. Virology 281 (2001) 216-230
81. Li X., Sambhara S., Li C.X., et al. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 188 (1998) 681-688
82. Li X., Sambhara S., Li C.X., et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269 (2000) 54-65
83. Kumar M., Behera A.K., Lockey R.F., et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 13 (2002) 1415-1425
84. Bembridge G.P., Rodriguez N., Garcia-Beato R., et al. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19 (2000) 1038-1046